We lead next-generation drug delivery platforms based on advanced technologies and devices.
Microneedle Platform Technology
Microneedle platform technology is an advanced transdermal drug delivery system that delivers drugs through microneedles approximately one-third the thickness of a human hair, penetrating the stratum corneum.
It offers improved convenience compared with conventional injections and enables application across diverse formulations.
01
Patient-Friendly and Non-Invasive Treatment
02
Fast and convenient drug delivery through simple application
03
Effective Drug Delivery Across the Skin Barrier
04
Tunable Drug Release through Customized Formulation Design
05
Improved Drug Stability by Avoiding Gastrointestinal Degradation and Hepatic First-Pass Metabolism
06
High-Efficiency Delivery of Active Ingredients with Reduced Drug Loss
Focus areas
Metabolic
Disorders
Improving the low bioavailability (BA) of macromolecular peptides and protein therapeutics via the transdermal route
Obesity
Diabetes
Growth hormone
Infectious Disease Prevention (Vaccination)
Microneedle-based vaccines support robust immune responses with reduced dose and minimal pain
Infectious diseases
Immunization
Vaccines
Dermatological Conditions and Skin Improvement
Localized drug delivery through enhanced skin penetration for treatment and aesthetic improvement
Acne
Hyperpigmentation
Wrinkle improvement
Metabolic
Disorders
Improving the low bioavailability (BA) of macromolecular peptides and protein therapeutics via the transdermal route
Obesity
Diabetes
Growth hormone
Infectious Disease Prevention (Vaccination)
Microneedle-based vaccines support robust immune responses with reduced dose and minimal pain
Infectious diseases
Immunization
Vaccines
Dermatological Conditions and Skin Improvement
Localized drug delivery through enhanced skin penetration for treatment and aesthetic improvement
Acne
Hyperpigmentation
Wrinkle improvement
Core Competency
Defining new paradigms in treatment through advanced technology and differentiated research
Core Competency 01
CLOPAM® (Closed-Packed Aero-Pressured Microneedle) Technology
– Patented Microneedle Manufacturing Platform
The core of a microneedle platform lies in its ability to achieve precise control for scalable mass production.
Daewoong Pharmaceutical has fundamentally addressed the key limitations of conventional microneedle manufacturing—namely production time, yield, and quality uniformity—through its proprietary CLOPAM® process.
By applying precision drug loading and an aerodynamic fabrication method, the technology enables fine-tuned control over both microneedle morphology and drug content at a micro-scale level. This allows for the stable mass production of microneedle products with highly consistent quality compared to conventional manufacturing approaches.
01
Precision Dosing
A proprietary automated dispensing system ensures accurate and quantified drug distribution into each individual micro-well within the mold.
02
Aerodynamic Crafting
A patented air-pressure drying process concentrates the drug at the needle tip, enhancing both bioavailability (BA) and pharmacokinetics (PK).
CLOPAM® DMAP
03
Absolute Protection
To prevent quality degradation caused by physical impact or air exposure during transportation and storage, the microneedles are securely packaged while remaining attached to the manufacturing mold.
Core Competency 02
Integrated GMP‑Based Microneedle R&D, Manufacturing, and Quality Infrastructure
Daewoong Pharmaceutical has established a GMP‑certified production infrastructure for microneedles, enabling all processes—from early R&D to pilot manufacturing—to be performed within a single facility.
This minimizes process‑to‑process variability arising from material transfer and greatly accelerates development timelines.
Moreover, the system ensures stable quality consistency from pilot production through to commercialization.
Based on an integrated system that connects research, development, and manufacturing in a single continuous workflow, Daewoong Pharmaceutical enables rapid and reliable development of microneedle products.
01
Integrated GMP Platform (End‑to‑End GMP Production System from R&D to Pilot Manufacturing)
Built on a pharmaceutical microneedle‑dedicated GMP‑certified facility, Daewoong Pharmaceutical has created an environment where formulation development, process optimization, pilot manufacturing, and clinical‑trial sample production can all be carried out in one place.
This integrated infrastructure enables direct scale‑up of data generated at the R&D stage to pilot and clinical‑trial sample levels, supporting the implementation of a fully internal quality management system—based on Quality by Design (QbD)—across the entire pre‑commercialization lifecycle.
02
In‑House Quality Evaluation Infrastructure Aligned with MFDS Microneedle Quality Assessment Guidelines
Daewoong Pharmaceutical has installed equipment that aligns with the MFDS microneedle quality assessment guidelines within the same facility, including Franz diffusion cells, hardness testers, and HPLC systems.
This allows key quality attributes such as physical properties, drug content, and permeability to be managed at GMP‑compliant standards without relying on external outsourcing.
Microscope
Microneedle Morphology Evaluation
Universal Testing Machine (UTM)
Microneedle Strength Evaluation
Franz Diffusion Cell
Microneedle Skin Permeation Study
Core Competency 03
Customized Microneedle & Applicator Development by Product Characteristics
By considering the physicochemical properties of drugs and their skin permeation profiles, key parameters—such as needle length, array configuration, density, and substrate thickness—are precisely engineered. This structural optimization maximizes drug release efficiency and delivery accuracy.
Daewoong Pharmaceutical also possesses proprietary applicator (insertion device) development capabilities that reflect product-specific use environments and usability requirements. This enables customized microneedle delivery systems that ensure optimal insertion force, ease of use, and reproducibility across different application sites.
01
Customized Mold Design
Unlike conventional approaches that rely on standardized molds, Daewoong enables flexible design of microneedle geometry—including height, diameter, array density, and tip shape—based on administration site, drug loading, and formulation type (prescription drugs, OTC products, and cosmetics).
This design flexibility allows precise control over drug loading efficiency, release kinetics, and penetration depth, making it a key capability for developing optimized formulations tailored to specific therapeutic or cosmetic objectives.
02
Specialized Applicator Design
Daewoong Pharmaceutical can design its own applicators to control pressure, insertion depth, and contact area based on the thickness, elasticity, and curvature of each skin site.
This ensures consistent insertion force and reproducibility regardless of user experience or anatomical variation, enabling safe and stable application from sensitive areas (e.g., face, neck) to thicker regions (e.g., arm, back).